Patent application number | Description | Published |
20100035976 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog - A method of treating a tumor or a viral disease by administering to a human the following 2′,5′-oligoadenylate analog: | 02-11-2010 |
20110046360 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR - Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides. | 02-24-2011 |
20110285925 | Display Device - A display device includes:
| 11-24-2011 |
20110286164 | STAND AND DISPLAY DEVICE INCLUDING STAND - A stand includes: a base including a front arm and a rear arm each in which a rod including thread parts at both ends is bent with the both ends facing each other; a hinge unit including two joint members each of which has at least two through-holes, and arranged such that the thread part at the one end of the front arm and the thread part at the one end of the rear arm screw into one of the through-holes of the two joint members, and the thread part at the other end of the front arm and the thread part at the other end of the rear arm screw into the other of the through-holes of the two joint members; and a bracket including an attachment fixed onto an object to be supported, and fixed onto the two joint members. | 11-24-2011 |
20120220649 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE - The present invention provides a double-stranded polynucleotide having a sense strand polynucleotide consisting of a nucleotide sequence complementary to a target sequence in a target gene, and an antisense strand polynucleotide having a nucleotide sequence complementary to the sense strand polynucleotide, wherein an aryl or heteroaryl compound is bound to a phosphate group at the 5′-end of the antisense strand polynucleotide. | 08-30-2012 |
20130075243 | SWITCH DEVICE, DISPLAY WITH SWITCH DEVICE, AND ELECTRONIC UNIT WITH SWITCH DEVICE - A switch device includes: a switch; an operation section disposed to face the switch; a first resilient section that is deformed by first pressing force derived from the operation section; and a second resilient section that is brought into contact with the switch by the deformation of the first resilient section, and is deformed to activate the switch by second pressing force greater than the first pressing force. | 03-28-2013 |
20130090465 | ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS - Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides. | 04-11-2013 |
20130253038 | Modified Single-Stranded Polynucleotide - It is intended to provide a polynucleotide that is resistant to RNase and has an RNA interference effect, etc. The present invention provides a single-stranded polynucleotide that is derived from a double-stranded polynucleotide comprising a sense strand polynucleotide corresponding to a target gene, and an antisense strand polynucleotide having a nucleotide sequence complementary to the sense strand polynucleotide, and has a structure in which the 5′-end of the antisense strand and the 3′-end of the sense strand are linked via a phenyl group-containing linker to form a phosphodiester structure at each of these ends. | 09-26-2013 |
20140316123 | ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS - Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides. | 10-23-2014 |